Under one in 10 patients that would benefit from GLP-1 drugs like Wegovy can access them, warns the WHO as it releases its first recommendations on the therapies.
Considering in excess of 1,000,000,000 individuals worldwide currently living with obesity, it is calling for broader and more equitable access to GLP-1 medication.
Per forecasts, in excess of 2,000,000,000 will be obese by 2030 without intervention.
"Our new guidance affirms that obesity is a lifelong illness that can be managed with comprehensive and lifelong treatment," said its chief Tedros Adhanom Ghebreyesus.
Substantial prices, limited production capacity, and supply-chain constraints are significant barriers to broad availability to the jabs that can assist patients in reducing significant weight, notes the body.
GLP-1 Therapy Shortage
Despite the present best projected case, the supply of GLP-1 therapies might only reach about 100 million people – under 10% of the global need, per the health organization.
The advice calls on governments and firms to widen access, via approaches including patent sharing.
A patent on a key compound – the core component of Novo Nordisk's Wegovy – is scheduled to end in a number of countries in 2026.
The Way Weight-Loss Injections Function
These medications imitate a natural hormone to reduce digestion speed, suppress the appetite and increase satiety so people eat less.
Patients usually start to lose weight after several weeks of beginning the weekly injections.
Studies suggests people may regain a significant portion within a year of stopping the drug, when their normal appetite come back.
To be carrying excess weight elevates your chance for experiencing diseases, such as diabetes, cardiovascular issues, brain attack, and certain malignancies.
Excess weight concerns individuals in all nations and was responsible for 3.7 million deaths worldwide in 2024, according to the health agency.
